Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Renzo Emanuel Vera

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112216496. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 1 paper

Papers 10

  1. A Novel Emerin/Nesprin-3 Interaction Mediates Nuclear Size Changes Induced by Oncogenic KRAS in Pancreatic Cancer Cells. Co-author DOI 10.1080/10985549.2026.2670710↗
  2. The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer. First author DOI 10.1016/j.cellsig.2024.111584↗
  3. Paracrine regulation of pancreatic cancer cell response to chemotherapy by GLI2-collagen I signaling. Co-author DOI 10.1016/j.jbc.2025.110311↗
  4. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Co-author DOI 10.1073/pnas.2424051122↗
  5. Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer. Co-author DOI 10.1172/jci.insight.187799↗
  6. Epigenetic regulation of the tumor microenvironment: A leading force driving pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.07.005↗
  7. SUFU promotes GLI activity in a Hedgehog-independent manner in pancreatic cancer. Co-author DOI 10.1042/bcj20220439↗
  8. GLI1 interaction with p300 modulates SDF1 expression in cancer-associated fibroblasts to promote pancreatic cancer cells migration. Co-author DOI 10.1042/bcj20220521↗
  9. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. Co-author DOI 10.1016/j.jbc.2021.100634↗
  10. Stromal deactivation by CSF1: a new feature of the aggressive pancreatic cancer microenvironment. Co-author DOI 10.15252/embr.202050468↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martín E. Fernández-Zapico · 10 shared papers, 2020–2026 · strength 2.29
  2. Luis F. Flores · 3 shared papers, 2023–2026 · strength 0.63
  3. Ezequiel J. Tolosa · 3 shared papers, 2023–2025 · strength 0.58
  4. David R Pease · 3 shared papers, 2023–2025 · strength 0.55
  5. Brooke R Tader · 2 shared papers, 2025–2026 · strength 0.46
  6. Kayla C. LaRue-Nolan · 2 shared papers, 2025–2026 · strength 0.46
  7. John Y. Kwon · 1 shared paper, 2025 · strength 0.42
  8. Huocong Huang · 1 shared paper, 2025 · strength 0.22
  9. Rolf A. Brekken · 1 shared paper, 2025 · strength 0.22
  10. Noemí Manero‐Rupérez · 1 shared paper, 2025 · strength 0.20
  11. Judith Vinaixa · 1 shared paper, 2025 · strength 0.20
  12. Patricia Santofimia‐Castaño · 1 shared paper, 2025 · strength 0.20
  13. Neus Martínez‐Bosch · 1 shared paper, 2025 · strength 0.20
  14. Pilar Navarro · 1 shared paper, 2025 · strength 0.20
  15. Juan Iovanna · 1 shared paper, 2025 · strength 0.20
  16. Aleksey V. Matveyenko · 1 shared paper, 2025 · strength 0.19
  17. Catherine E. Hagen · 1 shared paper, 2025 · strength 0.19
  18. Rondell Patrell Graham · 1 shared paper, 2025 · strength 0.19
  19. Ryan Michael Carr · 1 shared paper, 2025 · strength 0.19
  20. Christopher L. Pin · 1 shared paper, 2025 · strength 0.19
  21. David W. Dawson · 1 shared paper, 2025 · strength 0.19
  22. Brooke D. Paradise · 1 shared paper, 2023 · strength 0.16
  23. Glancis L. Raja Arul · 1 shared paper, 2023 · strength 0.16
  24. Daniel Grasso · 1 shared paper, 2023 · strength 0.16
  25. Hu Li · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.